BiomEdit closes Series B financing round exceeding $18m

BiomEdit, a biotech firm focused on microbiome-based tools for animal health, has closed an oversubscribed Series B financing round exceeding $18 million. The funding, led by Anterra Capital with participation from Nutreco and others, will support the regulatory approval and commercialization of its probiotic product, BE-101, aimed at reducing necrotic enteritis in poultry.

Original excerpt: A biotech company engineering next-generation microbiome-based tools for animal health, BiomEdit has successfully closed an oversubscribed Series B financing round exceeding $18m…

Source: AgTechNavigator.com